Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Arcus Biosciences stock | $24.82

Learn how to easily invest in Arcus Biosciences stock.

Arcus Biosciences, Inc
NYSE: RCUS - USD
BIOTECHNOLOGY
$33.89
+$2.22 (+7.01%)

Arcus Biosciences, Inc is a biotechnology business based in the US. Arcus Biosciences shares (RCUS) are listed on the NYSE and all prices are listed in US Dollars. Arcus Biosciences employs 236 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Arcus Biosciences

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RCUS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Arcus Biosciences stock price (NYSE: RCUS)

Use our graph to track the performance of RCUS stocks over time.

Arcus Biosciences shares at a glance

Information last updated 2021-07-23.
Latest market close$24.82
52-week range$16.69 - $42.36
50-day moving average $26.78
200-day moving average $31.37
Wall St. target price$54.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.59

Buy Arcus Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Arcus Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arcus Biosciences price performance over time

Historical closes compared with the close of $24.82 from 2021-05-28

1 week (2021-07-18) N/A
1 month (2021-06-29) -8.98%
3 months (2021-04-29) -25.73%
6 months (2021-01-25) N/A
1 year (2020-07-25) N/A
2 years (2019-07-25) N/A
3 years (2018-07-25) N/A
5 years (2016-07-25) N/A

Arcus Biosciences financials

Revenue TTM $85.2 million
Gross profit TTM $-81,831,000
Return on assets TTM -18.96%
Return on equity TTM -41.64%
Profit margin -196.76%
Book value $9.37
Market capitalisation $2.3 billion

TTM: trailing 12 months

Shorting Arcus Biosciences shares

There are currently 6.8 million Arcus Biosciences shares held short by investors – that's known as Arcus Biosciences's "short interest". This figure is 4.6% up from 6.5 million last month.

There are a few different ways that this level of interest in shorting Arcus Biosciences shares can be evaluated.

Arcus Biosciences's "short interest ratio" (SIR)

Arcus Biosciences's "short interest ratio" (SIR) is the quantity of Arcus Biosciences shares currently shorted divided by the average quantity of Arcus Biosciences shares traded daily (recently around 947245.45454545). Arcus Biosciences's SIR currently stands at 7.15. In other words for every 100,000 Arcus Biosciences shares traded daily on the market, roughly 7150 shares are currently held short.

However Arcus Biosciences's short interest can also be evaluated against the total number of Arcus Biosciences shares, or, against the total number of tradable Arcus Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arcus Biosciences's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Arcus Biosciences shares in existence, roughly 100 shares are currently held short) or 0.1502% of the tradable shares (for every 100,000 tradable Arcus Biosciences shares, roughly 150 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Arcus Biosciences.

Find out more about how you can short Arcus Biosciences stock.

Arcus Biosciences share dividends

We're not expecting Arcus Biosciences to pay a dividend over the next 12 months.

Arcus Biosciences share price volatility

Over the last 12 months, Arcus Biosciences's shares have ranged in value from as little as $16.69 up to $42.36. A popular way to gauge a stock's volatility is its "beta".

RCUS.US volatility(beta: 1.15)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Arcus Biosciences's is 1.1509. This would suggest that Arcus Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Arcus Biosciences overview

Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co. , Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer.

Stocks similar to Arcus Biosciences

Frequently asked questions

What percentage of Arcus Biosciences is owned by insiders or institutions?
Currently 36.881% of Arcus Biosciences shares are held by insiders and 58.475% by institutions.
How many people work for Arcus Biosciences?
Latest data suggests 236 work at Arcus Biosciences.
When does the fiscal year end for Arcus Biosciences?
Arcus Biosciences's fiscal year ends in December.
Where is Arcus Biosciences based?
Arcus Biosciences's address is: 3928 Point Eden Way, Hayward, CA, United States, 94545
What is Arcus Biosciences's ISIN number?
Arcus Biosciences's international securities identification number is: US03969F1093
What is Arcus Biosciences's CUSIP number?
Arcus Biosciences's Committee on Uniform Securities Identification Procedures number is: 03969F109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site